📈 This expansion will double their total footprint and boost manufacturing capacity by 50%.
🧪 The new facility will enhance their GMP manufacturing services and includes plans for additional cleanroom production lines.
💰 A £1.75M investment supports strategic growth, aiming to strengthen their presence in North America and the E.U.
Introduction:
The acquisition of a new biomanufacturing building by Symbiosis Pharmaceutical Services marks a significant strategic development in the company’s growth trajectory. This investment aims to enhance its operational capacity and service offerings in the biomanufacturing sector.
- Symbiosis Pharmaceutical Services has acquired a 20,000-square-foot biomanufacturing facility in Stirling, U.K., which will double the company’s overall footprint.
- The new site is anticipated to increase manufacturing capacity by 50% in the short term, enhancing the company’s current Good Manufacturing Practice (GMP) services.
- Located in Castle Business Park, the building will bring the total operational space to 43,500 square feet and will house two new cleanroom-based production lines.
- This expansion is part of a strategic initiative to enhance operational flexibility for various bespoke pharmaceutical manufacturing processes, increasing clinical trial and commercial supply capacity.
- The facility’s fit-out will take three years, with financial backing from Barclays Bank PLC for the purchase.
Conclusion:
The strategic acquisition is poised to position Symbiosis for sustained growth and to increase its market presence, particularly in North America and the E.U. by improving its service delivery in sterile injectable drug products.